High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction
- 31 January 2008
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 196 (1) , 365-371
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Screening for Type 2 DiabetesDiabetes Care, 2004
- Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular DiseaseCirculation, 2003
- Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000
- A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodiesClinica Chimica Acta, 1994
- Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy materialThe Journal of Pathology, 1992
- The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosisJACC, 1989
- Asymptomatic diabetic cardiomyopathy: a noninvasive studyDiabetes Research and Clinical Practice, 1988
- Left ventricular volumes determined by two-dimensional echocardiography in a normal adult populationJACC, 1983
- Treatment of myocardial infarction in a coronary care unitThe American Journal of Cardiology, 1967